Ketamine rescues anhedonia by cell-type- and input-specific adaptations in the nucleus accumbens
- PMID: 40112815
- PMCID: PMC12064382
- DOI: 10.1016/j.neuron.2025.02.021
Ketamine rescues anhedonia by cell-type- and input-specific adaptations in the nucleus accumbens
Abstract
Ketamine is recognized as a rapid and sustained antidepressant, particularly for major depression unresponsive to conventional treatments. Anhedonia is a common symptom of depression for which ketamine is highly efficacious, but the underlying circuits and synaptic changes are not well understood. Here, we show that the nucleus accumbens (NAc) is essential for ketamine's effect in rescuing anhedonia in mice subjected to chronic stress. Specifically, a single exposure to ketamine rescues stress-induced decreased strength of excitatory synapses on NAc-D1 dopamine receptor-expressing medium spiny neurons (D1-MSNs). Using a cell-specific pharmacology method, we establish the necessity of this synaptic restoration for the sustained therapeutic effects of ketamine on anhedonia. Examining causal sufficiency, artificially increasing excitatory synaptic strength onto D1-MSNs recapitulates the behavioral amelioration induced by ketamine. Finally, we used opto- and chemogenetic approaches to determine the presynaptic origin of the relevant synapses, implicating monosynaptic inputs from the medial prefrontal cortex and ventral hippocampus.
Keywords: AMPA receptors; D1 MSNs; anhedonia; ketamine; nucleus accumbens; prefrontal cortex; stress; sustained antidepressant response; synaptic plasticity; ventral hippocampus.
Copyright © 2025 The Author(s). Published by Elsevier Inc. All rights reserved.
Conflict of interest statement
Declaration of interests The authors declare no competing interests.
Update of
-
Ketamine rescues anhedonia by cell-type and input specific adaptations in the Nucleus Accumbens.bioRxiv [Preprint]. 2023 Jun 9:2023.06.08.544088. doi: 10.1101/2023.06.08.544088. bioRxiv. 2023. Update in: Neuron. 2025 May 7;113(9):1398-1412.e4. doi: 10.1016/j.neuron.2025.02.021. PMID: 37333325 Free PMC article. Updated. Preprint.
References
-
- US Burden of Disease Collaborators, Mokdad AH, Ballestros K, Echko M, Glenn S, Olsen HE, Mullany E, Lee A, Khan AR, Ahmadi A, et al. (2018). The State of US Health, 1990-2016: Burden of Diseases, Injuries, and Risk Factors Among US States. JAMA 319, 1444–1472. 10.1001/jama.2018.0158. - DOI - PMC - PubMed
-
- Rush AJ, Trivedi MH, Wisniewski SR, Nierenberg AA, Stewart JW, Warden D, Niederehe G, Thase ME, Lavori PW, Lebowitz BD, et al. (2006). Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am. J. Psychiatry 163, 1905–1917. 10.1176/ajp.2006.163.11.1905. - DOI - PubMed
-
- Trivedi MH, Rush AJ, Wisniewski SR, Nierenberg AA, Warden D, Ritz L, Norquist G, Howland RH, Lebowitz B, McGrath PJ, et al. (2006). Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am. J. Psychiatry 163, 28–40. 10.1176/appi.ajp.163.1.28. - DOI - PubMed
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Molecular Biology Databases
